Molecular pathways: Targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma

Clinical Cancer Research

Volumn 18, Issue 3, 2012, Pages 598-604

  Carbone, Michele ^a,b   Yang, Haining ^a,b  

^a UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^b UNIVERSITY OF HAWAII   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASBESTOS; BEVACIZUMAB; BORTEZOMIB; CARCINOGEN; CRYOPYRIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERIONITE; ERLOTINIB; ETANERCEPT; GEFITINIB; GLIBENCLAMIDE; HIGH MOBILITY GROUP B1 PROTEIN; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RANPIRNASE; RAPAMYCIN; REACTIVE OXYGEN METABOLITE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT TUMOR NECROSIS FACTOR; SCATTER FACTOR RECEPTOR; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANKYLOSING SPONDYLITIS; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNE DISEASE; CANCER INCIDENCE; CANCER INHIBITION; CANCER PREVENTION; CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; CELL ACTIVATION; CELL DEATH; CELL GROWTH; CELL SURVIVAL; CELL TRANSFORMATION; CHRONIC INFLAMMATION; COHORT ANALYSIS; CYTOKINE RELEASE; DISEASE ASSOCIATION; DISEASE COURSE; EARLY DIAGNOSIS; ENZYME ACTIVITY; ENZYME INHIBITION; FIBROSIS; GENE ACTIVITY; GENE MUTATION; GENETIC PREDISPOSITION; GOUT; HIGH RISK POPULATION; HUMAN; INFLAMMATION; LUNG FIBROSIS; MALIGNANT MESOTHELIOMA; MESOTHELIUM CELL; MOLECULAR DYNAMICS; MOLECULARLY TARGETED THERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SECRETION; PROTEIN SYNTHESIS; PSORIASIS VULGARIS; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR VOLUME; UVEA MELANOMA; WNT SIGNALING PATHWAY;

ASBESTOS; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; MESOTHELIOMA; ZEOLITES;

EID: 84863012595     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2259     Document Type: Review

References (60)

1. Carbone M, Ly BH, Dodson RF, Pagano I, Morris PT, Dogan UA, et al. Malignant mesothelioma: facts, myths and hypotheses. J Cell Physiol 2011;227:44-58.
2. Carbone M, Emri S, Dogan AU, Steele I, Tuncer M, Pass HI, et al. A mesothelioma epidemic in Cappadocia: scientific developments and unexpected social outcomes. Nat Rev Cancer 2007;7:147-54. (Pubitemid 46160990)
3. Coffin DLCP, Creason JP. Relative mesothelioma induction in rats by mineral fibers: comparison with residual pulmonary mineral fiber number and epidemiology. Inhal Toxicol 1992;4:8.
4. Burki T. Health experts concerned over India's asbestos industry. Lancet 2010;375:626-7.
5. Paoletti L, Batisti D, Bruno C, Di Paola M, Gianfagna A, Mastrantonio M, et al. Unusually high incidence of malignant pleural mesothelioma in a town of eastern Sicily: an epidemiological and environmental study. Arch Environ Health 2000;55:392-8.
6. Baumann F, Maurizot P, Mangeas M, Ambrosi JP, Douwes J, Robineau B. Pleural mesothelioma in New Caledonia: associations with environmental risk factors. Environ Health Perspect 2011;119: 695-700.
7. Pan XL, Day HW, Wang W, Beckett LA, Schenker MB. Residential proximity to naturally occurring asbestos and mesothelioma risk in California. Am J Respir Crit Care Med 2005;172:1019-25. (Pubitemid 41476540)
8. Maher B. Epidemiology: fear in the dust. Nature 2010;468:884-5.
9. Carbone M, Baris YI, Bertino P, Brass B, Comertpay S, Dogan AU, et al. Erionite exposure in North Dakota and Turkish villages with mesothelioma. Proc Natl Acad Sci U S A 2011;108:13618-23.
10. Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 2011;43:1022-5.
11. Wiesner T, Obenauf AC, Murali R, Fried I, Griewank KG, Ulz P, et al. Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet 2011;43:1018-21.
12. Bott M, Brevet M, Taylor BS, Shimizu S, Ito T, Wang L, et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet 2011;43:668-72.
13. Harbour JW, Onken MD, Roberson ED, Duan S, Cao L, Worley LA, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 2010;330:1410-3.
14. Fang Y, Fu D, Shen XZ. The potential role of ubiquitin c-terminal hydrolases in oncogenesis. Biochim Biophys Acta 2010;1806:1-6.
15. Ventii KH, Devi NS, Friedrich KL, Chernova TA, Tighiouart M, Van Meir EG, et al. BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization. Cancer Res 2008;68:6953-62.
16. Olofsson K, Mark J. Specificity of asbestos-induced chromosomal aberrations in short-term cultured human mesothelial cells. Cancer Genet Cytogenet 1989;41:33-9. (Pubitemid 19247989)
17. Choe N, Tanaka S, Kagan E. Asbestos fibers and interleukin-1 upregulate the formation of reactive nitrogen species in rat pleural mesothelial cells. Am J Respir Cell Mol Biol 1998;19:226-36. (Pubitemid 128354185)
18. Xu A, Huang X, LienYC, Bao L, Yu Z, Hei TK. Genotoxic mechanisms of asbestos fibers: role of extranuclear targets. Chem Res Toxicol 2007;20:724-33. (Pubitemid 46953679)
19. Heintz NH, Janssen-Heininger YM, Mossman BT. Asbestos, lung cancers, and mesotheliomas: from molecular approaches to targeting tumor survival pathways. Am J Respir Cell Mol Biol 2010;42: 133-9.
20. Fubini B, Hubbard A. Reactive oxygen species (ROS) and reactive nitrogen species (RNS) generation by silica in inflammation and fibrosis. Free Radic Biol Med 2003;34:1507-16. (Pubitemid 36638711)
21. Cacciotti P, Libener R, Betta P, Martini F, Porta C, Procopio A, et al. SV40 replication in human mesothelial cells induces HGF/Met receptor activation: a model for viral-related carcinogenesis of human malignant mesothelioma. Proc Natl Acad Sci U S A 2001;98:12032-7. (Pubitemid 32959821)
22. Wilson SM, Barbone D, Yang TM, Jablons DM, Bueno R, Sugarbaker DJ, et al. mTOR mediates survival signals in malignant mesothelioma grown as tumor fragment spheroids. Am J Respir Cell Mol Biol 2008;39:576-83.
23. Cheng JQ, Jhanwar SC, Klein WM, Bell DW, Lee WC, Altomare DA, et al. p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res 1994;54:5547-51.
24. Kratzke RA, Otterson GA, Lincoln CE, Ewing S, Oie H, Geradts J, et al. Immunohistochemical analysis of the p16INK4 cyclin-dependent kinase inhibitor in malignant mesothelioma. J Natl Cancer Inst 1995;87: 1870-5. (Pubitemid 3012655)
25. Xio S, Li D, Vijg J, Sugarbaker DJ, Corson JM, Fletcher JA. Codeletion of p15 and p16 in primary malignant mesothelioma. Oncogene 1995;11:511-5.
26. Sekido Y, Pass HI, Bader S, Mew DJ, Christman MF, Gazdar AF, et al. Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res 1995;55:1227-31.
27. Bianchi AB, Mitsunaga SI, Cheng JQ, Klein WM, Jhanwar SC, Seizinger B, et al. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc Natl Acad Sci U S A 1995;92:10854-8.
28. Altomare DA, Menges CW, Pei J, Zhang L, Skele-Stump KL, Carbone M, et al. Activated TNF-alpha/NF-kappaB signaling via down-regulation of Fas-associated factor 1 in asbestos-induced mesotheliomas from Arf knockout mice. Proc Natl Acad Sci U S A 2009;106:3420-5.
29. Jongsma J, van Montfort E, Vooijs M, Zevenhoven J, Krimpenfort P, van der Valk M, et al. A conditional mouse model for malignant mesothelioma. Cancer Cell 2008;13:261-71. (Pubitemid 351318370)
30. Hillegass JM, Shukla A, Lathrop SA, MacPherson MB, Beuschel SL, Butnor KJ, et al. Inflammation precedes the development of human malignant mesotheliomas in a SCID mouse xenograft model. Ann N Y Acad Sci 2010;1203:7-14.
31. Yang H, Bocchetta M, Kroczynska B, Elmishad AG, Chen Y, Liu Z, et al. TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis. Proc Natl Acad Sci U S A 2006;103:10397-402. (Pubitemid 44051178)
32. Choe N, Tanaka S, Xia W, Hemenway DR, Roggli VL, Kagan E. Pleural macrophage recruitment and activation in asbestos-induced pleural injury. Environ Health Perspect 1997;105[Suppl 5]:1257-60.
33. Wang Y, Faux SP, Hallden G, Kirn DH, Houghton CE, Lemoine NR, et al. Interleukin-1beta and tumour necrosis factor-alpha promote the transformation of human immortalised mesothelial cells by erionite. Int J Oncol 2004;25:173-8.
34. Franchi L, Eigenbrod T, Muñoz-Planillo R, Nuñez G. The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat Immunol 2009;10: 241-7.
35. Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol 2009;27:229-65.
36. Yang H, Rivera Z, Jube S, Nasu M, Bertino P, Goparaju C, et al. Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation. Proc Natl Acad Sci U S A 2010;107:12611-6.
37. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 2007;81:1-5. (Pubitemid 46028489)
38. Dostert C, Pétrilli V, Van Bruggen R, Steele C, Mossman BT, Tschopp J. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 2008;320:674-7. (Pubitemid 351928351)
39. Cassel SL, Eisenbarth SC, Iyer SS, Sadler JJ, Colegio OR, Tephly LA, et al. The Nalp3 inflammasome is essential for the development of silicosis. Proc Natl Acad Sci U S A 2008;105:9035-40.
40. Piguet PF, Vesin C. Treatment by human recombinant soluble TNF receptor of pulmonary fibrosis induced by bleomycin or silica in mice. Eur Respir J 1994;7:515-8. (Pubitemid 24099014)
41. Liu JY, Brass DM, Hoyle GW, Brody AR. TNF-alpha receptor knockout mice are protected from the fibroproliferative effects of inhaled asbestos fibers. Am J Pathol 1998;153:1839-47. (Pubitemid 28550671)
42. Ellerman JE, Brown CK, de Vera M, Zeh HJ, Billiar T, Rubartelli A, et al. Masquerader: high mobility group box-1 and cancer. Clin Cancer Res 2007;13:2836-48. (Pubitemid 46850704)
43. Jube S, Rivera Z, Gaudino G, Pass HI, Bianchi ME, Carbone M, et al. HMGB1, a potential new target for mesothelioma therapy [abstract 2600]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; Orlando (FL); 2011. Philadelphia (PA): AACR; 2011. Abstract nr 2600.
44. Govindan R, Kratzke RA, Herndon JE 2nd, Niehans GA, Vollmer R, Watson D, et al. Cancer and Leukemia Group B (CALGB 30101). Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res 2005;11: 2300-4. (Pubitemid 40490190)
45. Mathy A, Baas P, Dalesio O, van Zandwijk N. Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial. Lung Cancer 2005;50:83-6. (Pubitemid 41297473)
46. Garland LL, Rankin C, Gandara DR, Rivkin SE, Scott KM, Nagle RB, et al. Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J Clin Oncol 2007;25:2406-13. (Pubitemid 46999211)
47. Abutaily AS, Collins JE, Roche WR. Cadherins, catenins and APC in pleural malignant mesothelioma. J Pathol 2003;201:355-62. (Pubitemid 37408255)
48. Uematsu K, Seki N, Seto T, Isoe C, Tsukamoto H, Mikami I, et al. Targeting the Wnt signaling pathway with dishevelled and cisplatin synergistically suppresses mesothelioma cell growth. Anticancer Res 2007;27[6B]:4239-42.
49. Strizzi L, Catalano A, Vianale G, Orecchia S, Casalini A, Tassi G, et al. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 2001;193:468-75. (Pubitemid 32266815)
50. Jackman DM, Kindler HL, Yeap BY, Fidias P, Salgia R, Lucca J, et al. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer 2008;113:808-14.
51. Sartore-Bianchi A, Gasparri F, Galvani A, Nici L, Darnowski JW, Barbone D, et al. Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma. Clin Cancer Res 2007;13:5942-51. (Pubitemid 47583922)
52. Nasu MCM, Gaudino G, Ly BH, Bertino P, Shimizu D, Morris P, et al. Ranpirnase interferes with NF-kB pathway andMMP9 activity, inhibiting malignant mesothelioma cell invasiveness and xenografts growth. Genes Cancer 2011;2:576-84.
53. Goparaju CM, Blasberg JD, Volinia S, Palatini J, Ivanov S, Donington JS, et al. Onconase mediated NFKb downregulation in malignant pleural mesothelioma. Oncogene 2011;30:2767-77.
54. Sterman DH, Haas A, Moon E, Recio A, Schwed D, Vachani A, et al. A trial of intrapleural adenoviral-mediated interferon-{alpha}2b gene transfer for malignant pleural mesothelioma. Am J Respir Crit Care Med 2011;184:1395-9.
55. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirinon long-termrisk ofdeath due tocancer: analysis of individual patient data from randomised trials. Lancet 2011;377:31-41.
56. Catalano A, Graciotti L, Rinaldi L, Raffaelli G, Rodilossi S, Betta P, et al. Preclinical evaluation of the nonsteroidal anti-inflammatory agent celecoxib on malignant mesothelioma chemoprevention. Int J Cancer 2004;109:322-8. (Pubitemid 38252758)
57. Hamada N, Maeyama T, Kawaguchi T, Yoshimi M, Fukumoto J, Yamada M, et al. The role of high mobility group box1 in pulmonary fibrosis. Am J Respir Cell Mol Biol 2008;39:440-7.
58. Piguet PF, Vesin C, Grau GE, Thompson RC. Interleukin 1 receptor antagonist (IL-1ra) prevents or cures pulmonary fibrosis elicited in mice by bleomycin or silica. Cytokine 1993;5:57-61. (Pubitemid 23098835)
59. Thrall RS, Vogel SN, Evans R, Shultz LD. Role of tumor necrosis factor-alpha in the spontaneous development of pulmonary fibrosis in viable motheaten mutant mice. Am J Pathol 1997;151:1303-10. (Pubitemid 27479760)
60. Lamkanfi M, Mueller JL, Vitari AC, Misaghi S, Fedorova A, Deshayes K, et al. Glyburide inhibits the Cryopyrin/Nalp3 inflammasome. J Cell Biol 2009;187:61-70.